Table 2.

Doses of each DOAC for approved indications in Europe, the USA, and Japan

	VTE prevention (V)		SPAF (S)		(S)/(V) daily dose ratio
	Dose	Area	Dose	Area
Dabigatran	220 mg OD	EU	150 mg BID 110 mg BID	EU, JP	1–1.4
			150 mg BID	US	–
Rivaroxaban	10 mg OD	EU, US	20 mg OD	EU, US	2
			15 mg OD	JP	–
Apixaban	2.5 mg BID	EU	5 mg BID	EU, US, JP	2
Edoxaban	30 mg OD	JP	60 mg OD 30 mg OD	EU, US, JP	2

The dose for edoxaban for SPAF has not yet been confirmed, though results of 30- and 60-mg administrations have been reported in phase III studies

OD once daily, BID twice daily, EU Europe, US United States of America, JP: Japan